New drug duo aims to shrink lung tumors without chemo
NCT ID NCT06865339
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before radiation can shrink tumors in people with locally advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 76 participants will receive three cycles of the drug combination, then radiation. The main goal is to see how many patients have a significant reduction in tumor activity on a PET scan. This approach avoids chemotherapy and aims to control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Einstein Comprehensive Cancer Center (MECCC)
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.